Mind Medicine (NASDAQ: MNMD) reported Q4 EPS of ($2.44). Net loss for the year ended December 31, 2023 was $95.7 million, compared to $56.8 million for the year ended December 31, 2022.

Business Update

The Company will host a virtual investor event on March 7, 2024 to provide 12-week data from the Phase 2 program for MM120 being developed for the treatment of GAD. Senior management and key opinion leaders will discuss the treatment landscape, market potential and commercial opportunity for MM120 in GAD and other psychiatric disorders.

For earnings history and earnings-related data on Mind Medicine (MNMD) click here.